Previous 10 | Next 10 |
Genmab A/S (NASDAQ: GMAB ) will receive a $30M payment from licensee Novartis (NYSE: NVS ) to account for lost royalties from blood cancer med Arzerra (ofatumumab). More news on: Genmab A/S, Novartis AG, Healthcare stocks news, Read more ...
Written by Nick Ackerman, co-produced by Stanford Chemist We last visited BlackRock Health Sciences Trust II ( BMEZ ) only a couple of months after its launch in January. Several months have passed, and this fund has been performing exceptionally well. While it has only been a few months...
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q2 earnings Read more ...
Genmab A/S (GMAB) Q2 2020 Results Conference Call August 12, 2020 12:00 PM ET Company Participants Jan van de Winkel - President & CEO Anthony Pagano - CFO Judith Klimovsky - CDO Anthony Mancini - EVP & COO Conference Call Participants Peter Verdult - Citi Wimal...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q2 2020 Earnings Call Aug 12, 2020 , 12:00 p.m. ET Operator Continue reading
Genmab (NASDAQ: GMAB ) : Q2 GAAP EPS of DKK51.35. Revenue of DKK5.45B (+604.2% Y/Y). Press Release More news on: Genmab A/S, Genmab A/S, Earnings news and commentary, Tech stocks news,
Danish biotech Genmab ( GMAB +0.6% ) reports H1 results . Highlights: More news on: Genmab A/S, Healthcare stocks news, Earnings news and commentary, , Read more ...
Health Canada has approved a subcutaneous formulation of Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceutical Companies' multiple myeloma med Darzalex (daratumumab), originally approved for intravenous administration. More news on: Johnson & Johnson, Genmab A/S, Halozyme ...
According to data published by the U.S. Social Security Administration (SSA) in December 2019, the median monthly benefit paid out to retired individuals is just $1,503. For disabled individuals, the average monthly benefit was just $1,258. The SSA estimates that approximately nine out of 10 per...
Genmab A/S (NASDAQ: GMAB ) announces positive results from an open-label Phase 3 clinical trial, APOLLO , evaluating a subcutaneous formulation of licensor Janssen Biotech's [a unit of Johnson & Johnson (NYSE: JNJ ) ] Darzalex (daratumumab), combined with pomalidomide and dexametha...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...